With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics said it would submit its Alzheimer’s disease treatment for FDA approval despite mixed results from two ...

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease ...

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...

Shares of Axsome Therapeutics (AXSM) fell over 11% in Monday morning trade after it posted mixed results of its Alzheimer’s ...

Cases of a wretched stomach bug are surging in parts of the United States this winter, according to government data. The most recent numbers from the U.S. Centers for Disease Control and ...

US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...

Shares of Axsome Therapeutics (AXSM) are under pressure on Monday after the company reported mixed results for a pair of studies of its ...

Wells Fargo says that while the ADVANCE-2 miss makes the regulatory path less certain, the totality of the data supports approval for Axsome Therapeutics (AXSM)’ AXS-05 in Alzheimer’s disease ...

Axsome plans to submit an NDA for AXS-05 in Alzheimer’s disease agitation to the FDA in the second half of 2025, based on the efficacy and safety data from the above controlled and long-term studies.